Article citationsMore>>
Bang, Y.J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., Aprile, G., Kulikov, E., Hill, J., Lehle, M., Rüschoff, J. and Kang, Y.K., ToGA Trial Investigators (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697.
http://dx.doi.org/10.1016/S0140-6736(10)61121-X
has been cited by the following article:
-
TITLE:
HER-2/Neu Status in Gastric Carcinomas in a Series of Egyptian Patients and Its Relation to Ki-67 Expression
AUTHORS:
Saba El-Gendi, Iman Talaat, Mona Abdel-Hadi
KEYWORDS:
Egypt, FISH, Gastric Carcinoma, HER-2/Neu, Immunohistochemistry, Ki-67
JOURNAL NAME:
Open Journal of Pathology,
Vol.5 No.4,
August
17,
2015
ABSTRACT: Objective: HER-2/neu status in gastric
carcinomas (GCs) has not been studied before in the Egyptian population.
Materials and Methods: Seventy-three GCs were evaluated for the expression of
HER-2/neu and Ki-67 using immunohistochemistry (IHC). Fluorescence in situ
Hybridization (FISH) was done for HER2/neu IHC score 2+ cases. Results: Out of
the 73 gastric carcinomas, 23 (31.5%) were score 0, 17 (23.3%) were score 1+,
23 (31.5%) were score 2+, and 10 (13.7%) were score 3+. FISH analysis revealed
that the HER-2/neu gene was amplified in 11 out of the 23 cases (47.8%) scored
2+ by IHC. Therefore, the overall HER-2/neu positivity rate was 28.8% and it
was significantly associated with higher T-stage and lymphovascular invasion
(LVI). The Ki-67 expression rate ranged between 10% and 100%, with 84.9% of the
cases (n = 62) featuring high Ki-67 scores. High Ki-67 score was significantly
associated with male sex, tumor grade, and number of positive nodes. HER-2/neu
protein expression correlated significantly with Ki-67 score. Twenty tumors
showed combined HER-2/neu positivity and high Ki-67 score and were
significantly associated with higher T-stage and occurrence of LVI, implying a
more aggressive behavior. Conclusions: The rate of HER-2/neu positive GCs in
our series simulates universal rates, thereby mandating routine evaluation of
HER-2/neu status in all GCs submitted to our laboratory to benefit from
trastuzumab therapy. Further studies on a larger number of GCs are required to
prove that the concurrent HER-2/neu positivity and high Ki-67 score are markers
of worse prognosis.
Related Articles:
-
Mohamed A. Ibrahem
-
Masahide Ikeguchi, Hiroaki Saito, Yasunari Miki, Takayuki Kimura
-
Sead Kadric, Hanns Mohler, Olli Kallioniemi, Karl Heinz Altmann
-
Olivier Dubreuil, Aziz Zaanan, Olivier Pellerin, Jean-Baptiste Bachet, Philippe Rougier, Julien Taieb
-
Nayi Zongo, Bagué Abdoul Halim, Ouangré Edgar, Bagré Sidpawalmde Carine, Zida Maurice, Boukoungou Gilbert, Sanou Adama, Lompo Olga Mélanie, Traoré Si Simon, Ahmadou Dem